Related Experiment Video
Updated: Aug 6, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Three years' experience with infliximab in recalcitrant psoriasis
1City of Dublin Skin and Cancer Hospital, and St. Vincent's University Hospital, Dublin, Ireland. kashifaa2002@gmail.com
Clinical and Experimental Dermatology
|August 12, 2006
Summary
Infliximab demonstrated impressive efficacy and rapid action for severe psoriasis patients. However, its use is limited by side effects and the need for concomitant methotrexate, with ongoing concerns about immunosuppression.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Retrospective study evaluating infliximab for severe, treatment-resistant psoriasis.
- Focus on recalcitrant cases including chronic plaque psoriasis, pustular palmoplantar psoriasis, and Hallopeau's acrodermatitis continua.
Purpose of the Study:
- To assess the efficacy and safety of infliximab in patients with severe psoriasis.
- To report clinical experience with infliximab treatment for refractory psoriasis cases.
Main Methods:
- Twelve patients received infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks.
- Methotrexate was added weekly (5-7.5 mg) due to treatment resistance in two patients.
- Treatment response was evaluated using physician global assessment.
Main Results:
- Nine patients achieved an excellent response, including the acrodermatitis continua case.
- Two patients developed resistance, and one showed no response.
- Side effects led to treatment discontinuation in eight patients over time.
Conclusions:
- Infliximab shows significant efficacy and rapid response in severe psoriasis.
- Treatment limitations include hospital admission requirements and the need for methotrexate.
- Concerns persist regarding potential tuberculosis reactivation and lymphoma induction due to immunosuppression.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.